

Evaluating the Effect of Underlying Pulmonary Disease on the Clinical Outcome and survival among Patients with COVID-19: Using Propensity Score Matching



Malihe Safari¹ , Fatemeh Ghadamgahi² , Javad Faradmal³ , Saeid Bashirian⁴ , Ali Reza Soltanian⁵ , Salman Khazaei⁶  and Ghodratollah Roshanaei^{7,*} 

¹Department of Biostatistics and Epidemiology, Arak University of Medical Sciences, Arak, Iran

²Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

³Department of Biostatistics, School of Public Health, Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

⁴Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

⁵Modeling of Noncommunicable Diseases Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

⁶Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran

⁷Department of Biostatistics, School of Public Health, Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Shahid Fahmideh Ave, 6517838695, Hamadan, Iran

Abstract:

Background: Coronavirus (COVID-19) is a life-threatening factor throughout the world. Having an underlying disease among the patients with this disease diminishes the clinical effectiveness and increases their mortality rate. Hence, the study was carried out to compare the clinical outcomes in patients with COVID-19 with and without pulmonary disease using propensity score matching.

Methods: This case-control study was conducted on 299 COVID-19 patients with pulmonary disease (case group) and 299 COVID-19 patients without pulmonary diseases (control group). Matching the patients in the case and control groups was done using propensity score matching. Logistic regression was used to assess the effect of factors on the patient's clinical outcome (recovery-death), and the Cox model was used to determine the factors affecting patient survival. Data were analyzed in R software.

Results: The mean (SD) of the patients' age in the case and control groups was 65.49 (15.55) and 65.67 (15.55), respectively. The results of the logistic regression model showed that age, pulmonary disease, nausea, and blood oxygen affect patient death. The results of the Cox proportional-hazards model indicated that the variables of age, blood oxygen, and pulmonary had a significant effect on patient survival.

Conclusion: Given the high mortality rate among patients with COVID-19 and chronic pulmonary disease, these patients are considered a high-risk group and need special care.

Keywords: Pulmonary disease, COVID-19, Logistic regression, Cox proportional hazard, Matching, Propensity score.

© 2024 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Address correspondence to this author at the Department of Biostatistics, School of Public Health, Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Shahid Fahmideh Ave, 6517838695, Hamadan, Iran; Tel: +98 81 38380090; Fax: +98 81 38380509; E-mail: gh.roshanaei@umsha.ac.ir

Cite as: Safari M, Ghadamgahi F, Faradmal J, Bashirian S, Soltanian A, Khazaei S, Roshanaei G. Evaluating the Effect of Underlying Pulmonary Disease on the Clinical Outcome and survival among Patients with COVID-19: Using Propensity Score Matching. Open Public Health J, 2024; 17: e18749445268033. <http://dx.doi.org/10.2174/0118749445268033240103070544>



Received: August 10, 2023
Revised: November 22, 2023
Accepted: December 08, 2023
Published: January 12, 2024



Send Orders for Reprints to
reprints@benthamscience.net

1. BACKGROUND/INTRODUCTION

COVID-19 is a highly contagious and fatal infection caused by severe coronavirus disease, the acute respiratory syndrome virus [1]. From October 31, 2020, the coronavirus spread rapidly throughout the world (in more than 236 countries) with the global mortality rate continuing to increase, with an unprecedented effect on global economic performance [2]. Older patients and patients with chronic underlying diseases who have a weaker immune system are especially at greater risk and are more vulnerable [3]. Some patients may develop pneumonia or end in multiple organ failure or even death, while most patients have mild symptoms, and the overall mortality rate of diagnostic cases has been 3.4% [4]. In patients with underlying disease and older ones, the mortality rate was about 20%-22.7% [5, 6]. Most of those dying from COVID-19 have a history of cancer, hypertension, diabetes, or other chronic illnesses [5]. Although the studies on the effects of underlying diseases on the risk of patients with COVID-19 are increasing, most studies have been reported unadjusted because of the small sample size [7-10]. Nonetheless, the studies published have shown a higher risk of mortality in those with chronic underlying diseases compared to the general population with COVID-19 [11-17].

A major limitation of retrospective cohort studies is that they are at high risk for many research biases. To remove the effects of confounders as much as possible and to check fewer variables in the multivariable models due to low sample size, propensity score matching for disease severity and other variables has been utilized in some observational studies [18-20].

Hence, the purpose of the study was to examine the effect of pulmonary disease on the outcome of patients' treatment and to evaluate the factors affecting the survival of patients with COVID-19 according to a case-control study in Hamadan.

2. METHODS

2.1. The Study Design and the Participants

About 2459 patients who were admitted to Sina Hospital in Hamadan, Iran, from February 2020 to December 2020 due to COVID-19 disease were assessed in this study. Patients whose PCR test results were positive, had features compatible with COVID-19 at chest imaging (computed tomography, ultrasonography or radiography), or had severe clinical symptoms, such as shortness of breath or low blood oxygen levels, were included in our study. The underlying diseases of patients were extracted from medical records. In this case-control study, 299 pulmonary patients formed the case group, and 299 non-pulmonary patients were selected from 2160 non-pulmonary disease patients using the propensity score matching method based on age, smoking and other underlying diseases, including hypertension, diabetes, lung and heart disease as the control group. All patients

participating in this study were not vaccinated. Fig. (1) shows how to select a control group. All demographic characteristics of the patient, clinical characteristics, underlying diseases, clinical signs upon diagnosis, measures taken, and vital signs were obtained from patients' medical records. Lab findings and computed tomography (CT) images were carried out during hospitalization. The study was confirmed by the Ethics Committee (IR.UMSHA.REC. 1399.1050).

In this study, we included hospitalized COVID-19 cases, both confirmed with PCR or serological tests and those exclusively diagnosed based on clinical criteria (*i.e.*, symptoms, imaging, and laboratory results). Also, all patients who had incomplete information or were treated on an outpatient basis were excluded from the study.

2.2. Statistical Analysis

Quantitative variables were described by means (SD) and their mean was compared by t-test of two independent groups. Qualitative variables in both groups were described using frequency (%) and compared with the Chi-square test or Fisher's exact test. Matching was performed based on the propensity score by the nearest neighbor method with a ratio of (1: 1). Chi-square test and plotting were used for examining the variability of variables before and after matching. The aim was to achieve a balanced distribution of all the covariates in the propensity score-matched (PSM) cohort. Pulmonary diseases in this study included asthma 48%, COPD 41%, pneumonia 7%, and chronic bronchitis 3%. Fig. (2) shows the frequency of patients as well as the mortality rate of patients in different groups.

MatchIt, survival and survminer packages were used for matching and survival analyses. The logistic regression model was used to estimate the odds ratio of patients' death outcomes. Stepwise regression using the backward selection (Wald) method was also performed to obtain an optimal model and further validate the findings. The optimal model only included the variables that contributed significantly to the model. To compare the survival of patients for time from admission to death for patients who died (days), the Cox regression model was used. The findings were compared before and after matching. The analyses were carried out using R software version 3.6.2. The significance level of the tests was considered to be 5%.

3. RESULTS

Out of 2459 patients, 299 patients had pulmonary disease (case group), and 2160 did not. Table 1 shows the demographic and clinical characteristics of the patients. Before matching, Age, hypertension, and smoking in these subgroups were statistically significant ($p < 0.05$). Matching was carried out based on age, smoking and all underlying diseases. After matching, no significant differences were observed between the demographic and clinical variables of patients.




Fig. (1). A flowchart for the propensity score matching analysis.

The Cox proportional hazard model was turned to in the study to examine the effect of pulmonary disease on the survival of patients with COVID-19. The results of the univariable Cox regression model before and after matching for the pulmonary underlying disease are given in Table 2. Pulmonary disease before matching had no statistically significant effect on the survival of patients with COVID-19 ($p = 0.18$); however, after matching, the effect of this variable on survival was statistically significant ($p = 0.01$). Thus, one can state that the underlying pulmonary diseases affect the survival of patients with COVID-19. Table 3 presents the results of a simultaneous evaluation of these variables. The findings indicated that pulmonary disease, age and blood oxygen affected patient

survival ($p < 0.05$). The Hazard of death among the patients with the underlying pulmonary disease was 1.61 times higher than those without the disease. With a one-year increase in the patient's age, the hazard of death increased by 4%, and the hazard of death decreased by 5% with an increase of one unit in blood oxygen level. Furthermore, the survival function of the patients before (Fig. 3) and after matching (Fig. 4) in case and control groups using Kaplan-Meier plot was given for the time from admission to death (days). Fig. (4) shows that survival probability was statistically different in the two groups after matching, with the pulmonary disease patients having lower survival rates ($P < 0.05$).




Fig. (2). Types of pulmonary disease and their mortality rate.

Table 1. Demographic and clinical characteristics of the patients.

Characteristics	Before Matching			After Matching		
	Case Group (n=299)	Group Control (n=2160)	P-value	Case Group (n=299)	Group Control (n=299)	P-value
(SD \pm mean) Age	65.49 \pm 15.55	17.32 \pm 59.66	<0.01	15.55 \pm 65.49	15.55 \pm 65.68	0.85
Sex (male (%))	160 (53)	1155 (53)	1	160 (53)	161 (54)	1
Temperature (mean \pm SD)	37.32 \pm 0.76	0.76 \pm 37.33	0.84	37.32 \pm 0.76	0.80 \pm 37.38	0.38
Hypertension (yes (%))	122 (41)	725 (34)	0.02	122 (41)	115 (38)	0.62
Systolic BP (mean \pm SD)	19.84 \pm 123.20	18.62 \pm 121.10	0.08	19.84 \pm 123.20	18.14 \pm 124.70	0.33
Diastolic BP (mean \pm SD)	11.64 \pm 76.07	11.73 \pm 75.55	0.47	11.64 \pm 76.07	11.67 \pm 76.68	0.52
Smoking (yes (%))	61 (20)	132 (6)	<0.01	61 (20)	60 (20)	1
Heart disease (yes (%))	53 (18)	143 (6)	<0.01	53 (18)	40 (13)	0.18
Diabetes (yes (%))	51 (17)	408 (19)	0.49	51 (17)	54 (18)	0.83
Kidney failure (yes (%))	19 (6)	85 (4)	0.07	19 (6)	9 (3)	0.08
Other diseases (yes (%))	94 (31)	751 (35)	0.28	94 (31)	105 (35)	0.38
Death (%)	72 (24)	378 (17)	0.01	72 (24)	26 (9)	<0.01
Clinical Severity of Individual Patients						
Blood oxygen (mean \pm SD)	11.98 \pm 81.28	10.80 \pm 84.35	<0.01	11.98 \pm 81.28	11.14 \pm 84.58	<0.01
Percentage of lung involvement (mean (SD))	72.36 \pm 12.86	71.43 \pm 15.07	0.24	72.36 \pm 12.86	56.41 \pm 16.65	<0.01
Lymphocyte level ($10^9/L$) (mean (SD))	2.24 \pm 1.01	2.34 \pm 1.24	0.14	2.24 \pm 1.01	3.78 \pm 1.39	<0.01
Measures taken in the Hospital						
Length of hospitalization (mean \pm SD)	7.46 \pm 6.10	7.34 \pm 5.94	0.74	7.46 \pm 6.10	6.25 \pm 4.87	<0.01
ICU admission (yes (%))	99 (33)	609 (28)	0.09	99 (33)	55 (18)	<0.01
Oxygen therapy (%)	286 (96)	2050 (95)	0.68	286 (96)	280 (94)	0.36
Mechanical ventilation (%)	74 (25)	369 (17)	<0.01	74 (25)	26 (9)	<0.01
Length of ICU stay (days) (mean \pm SD)	2.48 \pm 5.76	2.23 \pm 5.48	0.47	2.48 \pm 5.76	1.30 \pm 4.29	<0.01
Patient Clinical Signs						
Asthma (yes (%))	225 (75)	1233 (57)	<0.01	225 (75)	184 (61)	<0.01

(Table 1) contd....

Characteristics	Before Matching			After Matching		
	Case Group (n=299)	Group Control (n=2160)	P-value	Case Group (n=299)	Group Control (n=299)	P-value
Diarrhea (yes) (%)	28 (9)	226 (10)	0.63	28 (9)	26 (9)	0.89
Dry cough (yes) (%)	101 (34)	936 (43)	<0.01	101 (34)	124 (41)	0.06
Sputum cough (yes) (%)	80 (27)	372 (17)	<0.01	80 (27)	59 (20)	0.05
Muscle pain (yes) (%)	117 (39)	934 (43)	0.20	117 (39)	104 (35)	0.31
Fever (yes) (%)	166 (55)	1159 (54)	0.59	(55)166	158 (53)	0.57
Chills (yes) (%)	164 (49)	990 (64)	0.36	(49)164	(46)126	0.12
Sore throat (yes) (%)	15 (5)	90 (4)	0.60	15 (5)	8 (3)	0.20
Nausea (yes) (%)	65 (22)	489 (23)	0.78	65 (22)	56 (19)	0.41
Headache (yes) (%)	44 (15)	374 (17)	0.30	44 (15)	47 (16)	0.82
Fatigue (yes) (%)	8 (3)	61 (3)	1	8 (3)	12 (4)	0.49
Vomit (yes) (%)	58 (19)	422 (19)	1	58 (19)	49 (16)	0.39
Runny nose (yes) (%)	1 (0)	12 (0)	1	1 (0)	1 (0)	1

Strata + lung disease=0 + lung disease=1




Fig. (3). Survival of patients before PSM.

Table 2. The results of the univariable Cox regression model after matching for the pulmonary underlying disease.

Characteristics (Reference)	Before Matching by PSM				After Matching by PSM			
	HR	95% CI		P-value	HR	95% CI		P-value
		Lower	Upper			Lower	Upper	
Sex	1.21	1.00	1.47	0.05	0.70	0.61	1.39	0.92
Age (male)	1.03	1.03	1.04	<0.01	1.04	1.02	1.06	<0.01
Hypertension (yes)	1.22	1.01	1.48	0.04	0.99	0.66	1.50	0.97
Smoking (yes)	1.03	0.73	1.47	0.85	1.05	0.65	1.70	0.85
pulmonary disease (yes)	1.20	0.92	1.58	0.18	1.77	1.14	2.74	0.01
Heart disease (yes)	1.37	0.93	2.21	<0.01	1.43	0.93	2.21	0.11
Diabetes (yes)	1.13	0.91	1.42	0.27	0.76	0.44	1.31	0.33
Kidney failure (yes)	1.24	0.80	1.92	0.34	1.19	0.48	2.93	0.71
Cancer (yes)	2.40	1.58	3.66	<0.01	1.66	0.23	12	0.61

(Table 2) contd....

Characteristics (Reference)	Before Matching by PSM				After Matching by PSM			
	HR	95% CI		P-value	HR	95% CI		P-value
		Lower	Upper			Lower	Upper	
Other diseases (yes)	1.15	0.95	1.39	0.16	0.83	0.53	1.29	0.42
Temperature	0.93	0.83	1.1	0.30	0.99	0.77	1.29	0.97
Blood oxygen	0.97	0.96	0.97	<0.01	0.95	0.94	0.96	<0.01
Asthmatic (yes)	1.15	0.94	1.41	0.16	0.76	0.45	1.29	0.31
Diarrhea (yes)	0.96	0.68	1.34	0.81	0.98	0.45	2.12	0.96
Dry cough (yes)	0.77	0.63	0.94	0.01	0.93	0.61	1.42	0.74
Muscles pain (yes)	0.75	0.62	0.92	<0.01	0.73	0.46	1.15	0.17
Fever (yes)	0.86	0.80	1.03	0.11	1.25	0.83	1.89	0.29
Chills (yes)	0.85	0.70	1.03	0.09	1.10	0.73	1.67	0.64
Sore throat (yes)	0.72	0.40	1.32	0.29	0.93	0.23	3.80	0.92
Nausea (yes)	0.96	0.77	1.20	0.75	1.56	1.00	2.45	0.05
Vomit (yes)	0.89	0.70	1.14	0.37	1.34	0.84	2.15	0.22
Fatigue (yes)	1.49	0.63	2.09	0.65	0.77	0.19	3.14	0.72
Headache (yes)	0.73	0.55	0.97	0.03	0.62	0.30	1.29	0.20
Sputum cough (yes)	0.88	0.68	1.13	0.31	0.76	0.45	1.29	0.31

Table 3. The results of the multivariate Cox regression model after matching for the pulmonary underlying disease.

Characteristics (Reference)	HR	95% CI		P-value
		Lower	Upper	
*Age	1.04	1.02	1.06	<0.01
pulmonary disease (yes)*	1.61	1.02	2.52	0.04
Blood oxygen level*	0.95	0.94	0.97	<0.01
Nausea (yes)	1.39	0.88	2.19	0.15


Note: * Statistically significant.**Fig. (4).** Survival of patients after PSM.

Table 4. Assessment of factors on clinical effect using univariable logistic regression in matched data.

Characteristics (Reference)	OR	95% CI		P-value
		Lower	Upper	
*Age	1.07	1.05	1.10	<0.01
Sex	1.05	0.68	1.67	0.81
Smoking	1.26	0.73	2.13	0.37
High blood pressure (yes)	1.18	0.75	1.85	0.47
Temperature	0.99	0.73	1.30	0.92
Blood oxygen level*	0.93	0.92	0.95	<0.01
pulmonary disease (yes)*	2.27	1.43	3.70	<0.01
Kidney failure (yes)	1.25	0.41	3.12	0.66
Diabetes (yes)	0.94	0.51	1.67	0.85
Heart disease (yes)*	2.27	1.39	3.70	<0.01
Cancer (yes)	0.77	0.04	4.35	0.81
Other diseases (yes)	0.94	0.58	1.51	0.82
Asthmatic (yes)*	1.96	1.18	3.45	0.01
Diarrhea (yes)	0.79	0.32	1.69	0.58
Dry cough (yes)	1.01	0.63	1.56	0.98
Muscles pain (yes)	0.66	0.40	1.05	0.09
Fever (yes)	1.03	0.66	1.61	0.89
Chills (yes)	0.99	0.63	1.54	0.95
Sore throat (yes)	0.51	0.08	1.75	0.36
Nausea (yes)*	2.04	1.23	3.33	<0.01
Vomit (yes)*	1.89	1.12	3.12	0.01
Fatigue (yes)	0.59	0.09	2.13	0.49
Headache (yes)	0.48	0.21	0.97	0.06
Sputum cough (yes)	0.70	0.39	1.20	0.22

Note: * Statistically significant.

Table 5. Assessment of factors on clinical effect using multivariable logistic regression in matched data.

Characteristics (Reference)	OR	95% CI		P-value
		Lower	Upper	
Age*	1.07	1.05	1.09	<0.01
pulmonary disease (yes)*	2.27	1.35	3.90	<0.01
Nausea (yes)*	2.15	1.20	3.81	<0.01
Blood oxygen*	0.94	0.93	0.96	<0.01

Note: * Statistically significant.

Additionally, unadjusted logistic regression was used after matching to assess the covariates of patients with COVID-19 on clinical outcomes (to identify significant variables that affect patient recovery) (Table 4). The effect of other diseases and laboratory and clinical symptoms were adjusted with multivariate logistic regression, whose results are given in Table 5. The results showed that having chronic pulmonary disease is an influential factor in the outcome of clinical of patients, so the odds of death in patients with the pulmonary disease is 2.27 times higher than in patients without it. Furthermore, based on the adjusted regression outcomes, besides pulmonary disease, age, nausea and blood oxygen level significantly affect patient mortality rate ($p < 0.05$).

4. DISCUSSION

In this case-control study, demographic, clinical and laboratory characteristics of 299 patients with chronic pulmonary disease and 299 without COVID-19 patients in Hamadan were examined. Then, the effects of the factors that affect the odds of death among them were determined using a logistic regression model and the factors affecting on survival of patients were evaluated using the Cox proportional hazard model.

Although age had been matched between case and control groups in the study, it was associated with patient survival; that is, the hazard of death in patients with COVID-19 increased with an increase in age. As the increase in age decreases the immune function of the body widely [15], older people and those with underlying diseases are affected by more severe infections of the

COVID-19 virus and are more likely to experience more adverse consequences [21, 22]. The cause of higher mortality rate in pulmonary patients in other studies was reported to be their advanced age [23, 24]. Additionally, the study results indicated that gender has no relationship with mortality that is in line with the results of other studies [16-20, 25-33].

Some other studies have approved the relationship between chronic diseases like diabetes and hypertension and mortality rate among COVID-19 patients [7-11, 18]. As the effect of other diseases had been modified in the study, the relationship between chronic pulmonary disease and clinical outcome with survival rate of patients with COVID-19 was significant and was in line with some studies too [34-36]. The mortality rate of the patients with pulmonary diseases was twice as high as other patients in the present study. Some studies revealed that viral infections could be related to exacerbation of pulmonary disease [14]. Furthermore, using immuno-suppression to treat pulmonary patients might increase COVID-19 risk [37].

Nonetheless, an unadjusted meta-analysis evaluated the patients with underlying diseases of COVID-19, arguing that many prevalent underlying diseases might be risk factors for exacerbating COVID-19 [8]. While reporting the results of a modified analysis, Guan *et al.* claimed that COVID-19 patients with any underlying disease had a lower prognosis compared to other patients [9]. In a study of 17 million patients in the UK, Drack *et al.* revealed that patients with chronic pulmonary disease were at higher risk than other COVID-19 patients (Relative Risk 1.95 (95% CI: 1.86-2.04)) and even the risk of death in them is higher than patients with cancer or heart disease [38]. In this study, the hazard of death among the pulmonary patients was 1.61 (confidence interval: 0.62-1.02) equal to other patients. Esposito *et al.* in America showed the mortality rate among patients with COVID-19 with chronic pulmonary disease was 3.2 times higher than in non-pulmonary patients [34]. The odds of mortality in pulmonary patients were 2.27 times higher than other patients in our study.

In the present study, the patients' main symptoms were 68.4% dyspnea, 54.2% fever, 45.5% chills, 37.6% dry cough, and 37% muscle pain in all patients. In Yang *et al.*, the symptoms were 78% fever, 74% dry cough, 37% pain, 37% sputum cough, and 35% dyspnea [8]. In Tian *et al.*, the critical symptoms were fever, dry cough, muscle pain, and sputum cough [39]. In Yang *et al.* and Tian *et al.*, fever and dry cough were the most important clinical symptoms among the patients [8, 39]. In other studies, similar to our study, dyspnea, cough and fever have been the key symptoms of the patients [7]. These symptoms have been considered as the factors affecting patient survival in some studies [40]. In the present study, only nausea was significant in the logistic regression model and was effective in the odds of patients' mortality. Logistic and Cox regression models revealed that blood oxygen level affects the survival of patients, and other symptoms do not significantly affect patient survival. Likewise, Park *et al.*

argued that symptoms like fever and dry cough can be considered as the primary causes of COVID-19 disease; however, when the symptoms worsen and become more severe, respiratory symptoms like dyspnea and lack of saturated oxygen can lead to death [41].

At the beginning of the coronavirus pandemic, most of the patients assessed in this study underwent drug therapy such as Azithromycin, Ceftriaxone, Kaletra, Lopinavir/ritonavir, Hydroxychloroquine, Ribavirin, Ceftriaxone and Vancomycin. However, patients today have more treatment options in the battle against coronavirus disease [42-47].

CONCLUSION

This study examined the effect of pulmonary disease on COVID-19 patients' survival and clinical outcomes by adjusting the effect of various factors. The findings revealed that patients with pulmonary disease will be at a higher mortality risk compared to other patients with COVID-19. Hence, they are naturally a vulnerable population with a higher mortality rate compared to the general population and thus require intensive care. Therefore, screening these patients and their identification and vaccination could diminish the mortality rate among these patients.

LIMITATIONS OF THE STUDY

This study had some limitations. First, the lack of detail in some clinical information of the patients made it impossible to evaluate the effect of this information on the investigated outcomes. Second, this was a retrospective study with underlying disease (such as underlying pulmonary disease) extracted from medical records, and we could not analyze the effects of the severity of COPD and other types of pulmonary disease on COVID-19. Third, this study was a single-center study and focused on one province of Iran (Hamadan) instead of all over the country. Therefore, certain aspects cannot be generalized. Finally, the diagnosis of types of pulmonary disease could have been underestimated, given that spirometry was not performed during the pandemic period, and the disease might have been even more prevalent.

LIST OF ABBREVIATIONS

HR	= Hazard Ratio
OR	= Odds Ratio
COVID	= Coronavirus Disease
CT	= Computed Tomography
PSM	= Propensity Score Matched
PCR	= Polymerase Chain Reaction
SD	= Standard Deviation
COPD	= Chronic Obstructive Pulmonary Disease
CI	= Confidence Interval

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The proposal of this study was approved by the

Institutional Review Board (IRB) of Hamadan University of Medical Sciences (ethical code: IR.UMSHA.REC.1400.004, project no: 14000207892).

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

All individual participants included in the study gave their informed consent for inclusion in the study and for publication of the manuscript.

STANDARDS OF REPORTING

STROBE guidelines were followed.

AVAILABILITY OF DATA AND MATERIALS

The data and materials that support the findings of this study are available from the corresponding author [G.R.] upon request.

FUNDING

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

We would like to thank the Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, for the approval and support of the study. This article is part of project number 9912199270 with the specific Ethics ID code IR.UMSHA.REC.1399.1050.

REFERENCES

- [1] Oxford AE, Halla F, Robertson EB, Morrison BE. Endothelial cell contributions to COVID-19. *Pathogens* 2020; 9(10): 785. <http://dx.doi.org/10.3390/pathogens9100785> PMID: 32992810
- [2] Wang Y, Yan X, Huang C, Sun Y, Yao C, Lin Y, *et al.* Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study. *Curr Med Res Opin* 2020; 1-16. PMID: 33210547
- [3] Zhang L, Zhu F, Xie L, *et al.* Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. *Ann Oncol* 2020; 31(7): 894-901. <http://dx.doi.org/10.1016/j.annonc.2020.03.296> PMID: 32224151
- [4] Coronavirus (COVID-19) Mortality rate. Available from: <https://www.worldometers.info/coronavirus/coronavirus-death-rate/> (Accessed 16 May 2020).
- [5] Novel Coronavirus Pneumonia Emergency Response Epidemiology. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41(2): 145-51. PMID: 32064853
- [6] Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020; 323(18): 1775-6. <http://dx.doi.org/10.1001/jama.2020.4683> PMID: 32203977
- [7] Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020; 395(10229): 1054-62. [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3) PMID: 32171076
- [8] Yang J, Zheng Y, Gou X, *et al.* Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. *Int J Infect Dis* 2020; 94: 91-5. <http://dx.doi.org/10.1016/j.ijid.2020.03.017> PMID: 32173574
- [9] Guan W, Liang W, Zhao Y, *et al.* Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. *Eur Respir J* 2020; 55(5): 2000547. <http://dx.doi.org/10.1183/13993003.00547-2020> PMID: 32217650
- [10] Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: Lessons from a pooled meta-analysis. *JCO Glob Oncol* 2020; 6(6): 557-9. <http://dx.doi.org/10.1200/GO.20.00097> PMID: 32250659
- [11] Wu C, Chen X, Cai Y, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180(7): 934-43. <http://dx.doi.org/10.1001/jamainternmed.2020.0994> PMID: 32167524
- [12] Shi S, Qin M, Shen B, *et al.* Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China. *JAMA Cardiol* 2020; 5(7): 802-10. <http://dx.doi.org/10.1001/jamacardio.2020.0950> PMID: 32211816
- [13] Cheng Y, Luo R, Wang K, *et al.* Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97(5): 829-38. <http://dx.doi.org/10.1016/j.kint.2020.03.005> PMID: 32247631
- [14] Azadeh N, Limper AH, Carmona EM, Ryu JH. The role of infection in interstitial lung diseases: A review. *Chest* 2017; 152(4): 842-52. <http://dx.doi.org/10.1016/j.chest.2017.03.033> PMID: 28400116
- [15] Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. *Transpl Int* 2009; 22(11): 1041-50. <http://dx.doi.org/10.1111/j.1432-2277.2009.00927.x> PMID: 19624493
- [16] Meng Y, Lu W, Guo E, *et al.* Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: A propensity score-matched analysis. *J Hematol Oncol* 2020; 13(1): 75. <http://dx.doi.org/10.1186/s13045-020-00907-0> PMID: 32522278
- [17] Chen N, Zhou M, Dong X, *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet* 2020; 395(10223): 507-13. [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7) PMID: 32007143
- [18] Ghadamgahi F, Tapak L, Bashirian S, Amiri R, Roshanaei G. The effect of underlying diabetes disease on clinical outcome and survival in patients with COVID-19: A propensity score matching study. *J Diabetes Metab Disord* 2021; 20(2): 1675-83. <http://dx.doi.org/10.1007/s40200-021-00922-z> PMID: 34746038
- [19] Meizlish ML, Goshua G, Liu Y, *et al.* Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID -19: A propensity score-matched analysis. *Am J Hematol* 2021; 96(4): 471-9. <http://dx.doi.org/10.1002/ajh.26102> PMID: 33476420
- [20] Ghadamgahi F, Safari M, Faradmal J, Bashirian S, Soltanian AR, Khazaei S, *et al.* Mortality rate and effects of COVID-19 in cancer patients non-cancer patients: A propensity score matching study. *Open Public Health J* 2023; 16(1)
- [21] Zhao Q, Meng M, Kumar R, *et al.* The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol* 2020; 92(10): 1915-21. <http://dx.doi.org/10.1002/jmv.25889> PMID: 32293753
- [22] Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). *Respir Med* 2020; 167: 105941. <http://dx.doi.org/10.1016/j.rmed.2020.105941> PMID: 32421537
- [23] Du RH, Liang LR, Yang CQ, *et al.* Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2. *Eur*

- Respir J 2020; 56(3): 2002961.
<http://dx.doi.org/10.1183/13993003.02961-2020> PMID: 32907886
- [24] Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, *et al.* Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterizations Protocol: Development and validation of the 4C Mortality Score. *BMJ* 2020; 370
<http://dx.doi.org/10.3390/diagnostics13152597> PMID: 37568963
- [25] Motoc NŞ, Făgărășan I, Urda-Cîmpean AE, Todea DA. Prognosis predictive markers in patients with chronic obstructive pulmonary disease and COVID-19. *Diagnostics* 2023; 13(15): 2597.
<http://dx.doi.org/10.3390/diagnostics13152597> PMID: 37568963
- [26] He Z, Zhong N, Guan WJ. Impact of chronic respiratory diseases on the outcomes of COVID-19. *Arch Bronconeumol* 2022; 58(1): 5-7.
<http://dx.doi.org/10.1016/j.arbres.2021.05.009> PMID: 34075267
- [27] Au Yeung SL, Li AM, He B, Kwok KO, Schooling CM. Association of smoking, lung function and COPD in COVID-19 risk: A two-step Mendelian randomization study. *Addiction* 2022; 117(7): 2027-36.
<http://dx.doi.org/10.1111/add.15852> PMID: 35220625
- [28] Awatade N, Wark P, Chan A, *et al.* The complex association between COPD and COVID-19. *J Clin Med* 2023; 12(11): 3791.
<http://dx.doi.org/10.3390/jcm12113791> PMID: 37297985
- [29] Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736\(20\)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5) PMID: 31986264
- [30] Wang D, Hu B, Hu C, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; 323(11): 1061-9.
<http://dx.doi.org/10.1001/jama.2020.1585> PMID: 32031570
- [31] Li Q, Guan X, Wu P, *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020; 382(13): 1199-207.
<http://dx.doi.org/10.1056/NEJMoa2001316> PMID: 31995857
- [32] Zhang J, Dong X, Cao Y, *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; 75(7): 1730-41.
<http://dx.doi.org/10.1111/all.14238> PMID: 32077115
- [33] Yang X, Yu Y, Xu J, *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *Lancet Respir Med* 2020; 8(5): 475-81.
- [34] Esposito AJ, Menon AA, Ghosh AJ, *et al.* Increased odds of death for patients with interstitial lung disease and COVID-19: A case-control study. *Am J Respir Crit Care Med* 2020; 202(12): 1710-3.
<http://dx.doi.org/10.1164/rccm.202006-2441LE> PMID: 32897754
- [35] Udwadia Z, Koul P, Dhooria S. The impact of COVID-19 on patients with preexisting interstitial lung disease: High mortality in these high-risk patients. *Lung India* 2021; 38(7): 1.
http://dx.doi.org/10.4103/lungindia.lungindia_60_21 PMID: 33686971
- [36] Gallay L, Uzunhan Y, Borie R, *et al.* Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. *Am J Respir Crit Care Med* 2021; 203(2): 245-9.
<http://dx.doi.org/10.1164/rccm.202007-2638LE> PMID: 33252997
- [37] Li X, Xu S, Yu M, *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020; 146(1): 110-8.
<http://dx.doi.org/10.1016/j.jaci.2020.04.006> PMID: 32294485
- [38] Drake TM, Docherty AB, Harrison EM, *et al.* Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. *Am J Respir Crit Care Med* 2020; 202(12): 1656-65.
<http://dx.doi.org/10.1164/rccm.202007-2794OC> PMID: 33007173
- [39] Tian J, Yuan X, Xiao J, *et al.* Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. *Lancet Oncol* 2020; 21(7): 893-903.
[http://dx.doi.org/10.1016/S1470-2045\(20\)30309-0](http://dx.doi.org/10.1016/S1470-2045(20)30309-0) PMID: 32479790
- [40] Liang W, Guan W, Chen R, *et al.* Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. *Lancet Oncol* 2020; 21(3): 335-7.
[http://dx.doi.org/10.1016/S1470-2045\(20\)30096-6](http://dx.doi.org/10.1016/S1470-2045(20)30096-6) PMID: 32066541
- [41] Park SW, Sun K, Viboud C, Grenfell BT, Dushoff J. Potential role of social distancing in mitigating spread of coronavirus disease, South Korea. *Emerg Infect Dis* 2020; 26(11): 2697-700.
<http://dx.doi.org/10.3201/eid2611.201099> PMID: 32795385
- [42] Lui G, Guaraldi G. Drug treatment of COVID-19 infection. *Curr Opin Pulm Med* 2023; 29(3): 174-83.
<http://dx.doi.org/10.1097/MCP.0000000000000953> PMID: 36917228
- [43] Jayk Bernal A, Gomes da Silva MM, Musungaie DB, *et al.* Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. *N Engl J Med* 2022; 386(6): 509-20.
<http://dx.doi.org/10.1056/NEJMoa2116044> PMID: 34914868
- [44] Rahmah L, Abarikwu SO, Arero AG, *et al.* Oral antiviral treatments for COVID-19: Opportunities and challenges. *Pharmacol Rep* 2022; 74(6): 1255-78.
<http://dx.doi.org/10.1007/s43440-022-00388-7> PMID: 35871712
- [45] Tiseo G, Barbieri C, Galfo V, *et al.* Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: The PISA Outpatient Clinic Experience. *Infect Dis Ther* 2022; 1-15.
 PMID: 36441485
- [46] Coronavirus (COVID-19) | Drugs. Available from: <https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-COVID-19-drugs>
- [47] COVID-19 medications and antivirals. Available from: <https://www.healthdirect.gov.au/COVID-19/medications>